These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

615 related articles for article (PubMed ID: 32406880)

  • 1. Enfortumab vedotin to treat urothelial carcinoma.
    Hanna KS
    Drugs Today (Barc); 2020 May; 56(5):329-335. PubMed ID: 32406880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
    Yu EY; Petrylak DP; O'Donnell PH; Lee JL; van der Heijden MS; Loriot Y; Stein MN; Necchi A; Kojima T; Harrison MR; Hoon Park S; Quinn DI; Heath EI; Rosenberg JE; Steinberg J; Liang SY; Trowbridge J; Campbell M; McGregor B; Balar AV
    Lancet Oncol; 2021 Jun; 22(6):872-882. PubMed ID: 33991512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Pharmacology of the Antibody-Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors.
    Tang M; Garg A; Bonate PL; Rosenberg JE; Matsangou M; Kadokura T; Yamada A; Choules M; Pavese J; Nagata M; Tenmizu D; Koibuchi A; Heo N; Wang L; Wojtkowski T; Hanley WD; Poondru S
    Clin Pharmacokinet; 2024 Apr; 63(4):423-438. PubMed ID: 38609704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma.
    Takahashi S; Uemura M; Kimura T; Kawasaki Y; Takamoto A; Yamaguchi A; Melhem-Bertrandt A; Gartner EM; Inoue T; Akazawa R; Kadokura T; Tanikawa T
    Invest New Drugs; 2020 Aug; 38(4):1056-1066. PubMed ID: 31444589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.
    Powles T; Rosenberg JE; Sonpavde GP; Loriot Y; Durán I; Lee JL; Matsubara N; Vulsteke C; Castellano D; Wu C; Campbell M; Matsangou M; Petrylak DP
    N Engl J Med; 2021 Mar; 384(12):1125-1135. PubMed ID: 33577729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.
    Rosenberg JE; O'Donnell PH; Balar AV; McGregor BA; Heath EI; Yu EY; Galsky MD; Hahn NM; Gartner EM; Pinelli JM; Liang SY; Melhem-Bertrandt A; Petrylak DP
    J Clin Oncol; 2019 Oct; 37(29):2592-2600. PubMed ID: 31356140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin.
    Lacouture ME; Patel AB; Rosenberg JE; O'Donnell PH
    Oncologist; 2022 Mar; 27(3):e223-e232. PubMed ID: 35274723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma.
    McGregor BA; Sonpavde G
    Expert Opin Investig Drugs; 2019 Oct; 28(10):821-826. PubMed ID: 31526130
    [No Abstract]   [Full Text] [Related]  

  • 9. Population Pharmacokinetic Modeling and Exposure-Response Analysis for the Antibody-Drug Conjugate Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Carcinoma.
    Zuo P; Bonate P; Garg A; Matsangou M; Tang M
    Clin Pharmacol Ther; 2024 Nov; 116(5):1278-1288. PubMed ID: 39039635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma.
    Mantia CM; Sonpavde G
    Expert Rev Anticancer Ther; 2022 May; 22(5):449-455. PubMed ID: 35466857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The biology and rationale of targeting nectin-4 in urothelial carcinoma.
    Heath EI; Rosenberg JE
    Nat Rev Urol; 2021 Feb; 18(2):93-103. PubMed ID: 33239713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
    Powles T; Valderrama BP; Gupta S; Bedke J; Kikuchi E; Hoffman-Censits J; Iyer G; Vulsteke C; Park SH; Shin SJ; Castellano D; Fornarini G; Li JR; Gümüş M; Mar N; Loriot Y; Fléchon A; Duran I; Drakaki A; Narayanan S; Yu X; Gorla S; Homet Moreno B; van der Heijden MS;
    N Engl J Med; 2024 Mar; 390(10):875-888. PubMed ID: 38446675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enfortumab Vedotin: Nursing Perspectives on the Management of Adverse Events in Patients With Locally Advanced or Metastatic Urothelial Carcinoma.
    Pace A; Brower B; Conway D; Leis D
    Clin J Oncol Nurs; 2021 Apr; 25(2):E1-E9. PubMed ID: 33739346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA Approves First Agent to Treat Locally Advanced, Metastatic Urothelial Cancer.
    Kahl KL
    Oncology (Williston Park); 2020 Jan; 34(1):11. PubMed ID: 32645199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Narrative review of value frameworks in urothelial carcinoma and positioning of enfortumab vedotin.
    Ortiz Nunez A; Gonzalez Portela J; Zozaya N; Fernández I
    J Med Econ; 2024; 27(1):1222-1231. PubMed ID: 39258976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enfortumab-vedotin use for urothelial carcinoma in two patients on hemodialysis.
    Khosla H; Bhatt S; Wang MJ; Gignac G; Mittal K; Patel J
    J Oncol Pharm Pract; 2024 Jul; 30(5):941-944. PubMed ID: 38470473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antibody-Drug Conjugates against Urothelial Carcinoma-Current Issues and Future Development].
    Ikarashi D; Obara W
    Gan To Kagaku Ryoho; 2024 Jul; 51(7):691-694. PubMed ID: 39191682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.
    Ning YM; Suzman D; Maher VE; Zhang L; Tang S; Ricks T; Palmby T; Fu W; Liu Q; Goldberg KB; Kim G; Pazdur R
    Oncologist; 2017 Jun; 22(6):743-749. PubMed ID: 28424325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Paradigm shift in systemic therapy for metastatic urothelial carcinoma-antibody-drug conjugates (ADCs) and fibroblast growth factor receptor (FGFR) inhibitors].
    Casuscelli J; von Amsberg G; Retz M
    Urologie; 2024 Oct; 63(10):1002-1010. PubMed ID: 39235511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma.
    Halford Z; Anderson MK; Clark MD
    Ann Pharmacother; 2021 Jun; 55(6):772-782. PubMed ID: 32945172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.